Mechanism of Action: The "Ion Trapping" Effect
Chloroquine belongs to the class of agents that disrupt heme metabolism. Its primary target is the malaria parasite. The process of parasite destruction occurs in several stages:
- Penetration: Drug molecules easily cross membranes and enter directly into the parasite's digestive vacuole.
- Ionization and Trapping: An acidic environment is maintained inside the vacuole. Upon entering, chloroquine becomes ionized. The ionized form loses its ability to cross lipid membranes back out, trapping the drug inside where its concentration increases manifold (this is the "ion trapping" effect).
- Cytotoxicity: The parasite feeds on host hemoglobin. Digestion produces an intermediate product, ferriprotoporphyrin IX (heme). Chloroquine binds to heme and blocks its polymerization into non-toxic hemozoin. As a result, toxic metabolic byproducts accumulate and kill the plasmodium from within.
Pharmacodynamics and Clinical Applications
Although historically a broad-spectrum antimalarial, its pharmacodynamic effects are much wider. The drug exerts potent anti-inflammatory and immunosuppressive actions.
These effects are mediated by a complex mechanism:
- Inhibition of phospholipase A2 activity.
- Stabilization of cell membranes.
- Significant antioxidant activity.
- General immunomodulation.
Consequently, clinical indications are divided into two main categories:
- Infectious Diseases: Treatment of amebiasis, as well as prophylaxis and treatment of all forms of malaria (provided the strain is susceptible).
- Rheumatology and Dermatology: Treatment of porphyria cutanea tarda, photosensitive dermatoses, and rheumatic diseases. For example, in rheumatoid arthritis, chloroquine is sometimes used in combination regimens (e.g., with methotrexate).
Plasmodial Resistance
A major challenge in modern infectious disease management is parasite resistance. The agent of malignant tertian malaria (Plasmodium falciparum) has developed robust resistance to chloroquine in most endemic regions.
- Mechanism of Resistance: The parasite has developed active efflux pumps (such as PfCRT - Plasmodium falciparum chloroquine resistance transporter) that actively pump drug molecules out of its digestive vacuole, preventing toxic concentrations from accumulating.
- Clinical Relevance: Despite resistance in P. falciparum, the drug remains a first-line agent for infections caused by P. vivax, P. ovale, P. malariae, and susceptible strains of P. falciparum.
Adverse Effects and Contraindications
The drug is characterized by an extremely slow elimination rate. Clearance occurs primarily via the kidneys and takes several months for complete elimination from the body.
High-dose or long-term therapy is associated with several severe adverse effects:
- Ocular Toxicity: One of the most serious complications. Corneal deposits/opacity and severe retinopathy (bull's-eye maculopathy) can occur.
- Gastrointestinal: Direct toxic effects, motility disturbances.
- Central Nervous System: Various neurological disturbances, including psychoses and seizures.
- Skin: Dermatitis, pruritus, and hyperpigmentation.
- Specific Toxicity: In patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, the drug precipitates acute hemolytic anemia.
Absolute Contraindications: Pregnancy (with certain exceptions for malaria prophylaxis, but generally avoided), psoriasis (can exacerbate skin lesions), pre-existing maculopathy, and severe hepatic or hematologic disorders unrelated to malaria.